new perspectives in thyroid cancer - osu center for ... - thyroid cancer final - 2.pdf · new...

1

New Perspectives inNew Perspectives inThyroid CancerThyroid Cancer

New Perspectives inNew Perspectives inThyroid CancerThyroid Cancer

Jennifer Sipos, MDAssistant Professor of Medicine

Di i i f E d i lDivision of EndocrinologyThe Ohio State University

• Thyroid Nodules

OutlineOutline

• Thyroid Nodules• Thyroid Cancer Epidemiology• Initial management• Long-term follow up• Disease-free statusDisease free status

2

Incidence of thyroid nodulesIncidence of thyroid nodules

60

70

10

20

30

40

50

reva

len

ce (

%) Autopsy/

Ultrasound

Palpation

Likelihood of malignancy 14%1

0

10

0 20 40 60 80 100

P

Age (years)

Mazzaferri 1993 NEJM 328 (8): 553-9

Palpation

1Yassa 2007 Cancer Cytopathology 111:508-16

How good are we at finding nodules?

Ultrasound vs. Palpation

How good are we at finding nodules?

Ultrasound vs. Palpation

Nodules FOUND by palpation Nodules MISSED by palpation

15

202530

35

42%

s fo

un

d b

y U

S

50%

05

10

<1cm 1‐2cm >2cm

Brander 1992 J Clin Ultrasound 20: 37-42

# N

od

ule 94%

Nodule size by US

3

TSH predicts malignancy risk and cancer stage

TSH predicts malignancy risk and cancer stage

TNM stage

No. of patients

Mean TSH

pvalue

I and II 204 2.1±0.240.002III and IV 35 4.9±1.59

Boelaert 2006 JCEM 91:4295-4301 Haymart, et al. JCEM, March 2008, 93(3):809–814

*p<0.05**p<0.01***p<0.001

FNA Cytology Diagnostic CategoriesFNA Cytology Diagnostic Categories

National Cancer InstituteClassification

Alternateclassification

% Malignant

Benign <1%

Follicular Lesion of Undetermined Significance

Atypia 5-10%

Neoplasm Follicular NeoplasmHurthle Neoplasm

20-30%

Suspicious for malignancy 50-75%

Malignant 98-100%

Non-diagnostic Unsatisfactory

Baloch ZW., 2008 Diag Cytopath 36:425-437

4

Percentages of thyroid carcinoma by

histologic subtype

Percentages of thyroid carcinoma by

histologic subtype

80%

11%

3%4% 2% Papillary

Follicular

Hurthle cell

Medullary

Anaplastic

Hundahl 1998 Cancer 83: 2368-48

Epidemiology of Thyroid Cancer

Epidemiology of Thyroid Cancer

• 48,020 new cases in 2011• 1 740 deaths1,740 deaths

• Females 5 year survival rates increasingsignificantly, from 93% in 1974 to 97.4% in 2001

• Survival rates in men have decreasedsignificantly, by 2.4%g y, y

• Rates of distant metastases in men were over 2-fold higher than women (9% vs 4%)

SEER Cancer Statistics Review, 1975-2001. http://seer.cancer.gov/csr/1975_2008/.

National Cancer Institute, http://www.cancer.gov/cancertopics/types/thyroid

Cancer Facts and Figures 2011

5

2.4-fold increase

Sipos, Mazzaferri. 2010 Clinical Oncology 22: 395-404

40

The prevalence of microcarcinoma in 24 autopsy series with 7,156 cases

The prevalence of microcarcinoma in 24 autopsy series with 7,156 cases

18-fold difference among studies

nce

r

10

15

20

25

30

35

wit

h t

hyr

oid

can

0

5

10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Adapted from: Pazaitou-Panayiotou, et al. 2007 Thyroid 17 (11): 1085-92

Study Number

Per

cen

t

6

2521 6

The Prevalence of PTMC in 11 Surgical Series with 6,942 Cases

The Prevalence of PTMC in 11 Surgical Series with 6,942 Cases

17-fold difference among studiesnce

r

10

15

20

5.17.1 7.2

10.5

16.4 16.7

21.617-fold difference among studies

wit

h t

hyr

oid

can

0

5

1 2 3 4 5 6 7 8 9 10 11

1.3 1.8 2.23.8

5.1

Per

cen

t

Study NumberAdapted from: Pazaitou-Panayiotou, et al. 2007 Thyroid 17 (11): 1085-92

Incidence rates of PTC by tumor sizeIncidence rates of PTC by tumor size

tio

n10

0,00

0 p

op

ula

tR

ate

per

Year DiagnosedCramer et al 2010 Surgery 148: 1147-52

7

Mortality and Mortality and Mortality and Mortality and yyRecurrence Rates Recurrence Rates for Thyroid Cancerfor Thyroid Cancer

yyRecurrence Rates Recurrence Rates for Thyroid Cancerfor Thyroid Cancer

Relative survival of papillary thyroid carcinoma by AMES risk levels

Relative survival of papillary thyroid carcinoma by AMES risk levels

“Low risk” deaths = 351“High risk” deaths = 191

erce

nt

surv

ival

Years after diagnosis

Hundahl et al 1998 Cancer 83: 2638

Pe

8

Ten year mortality by tumor size

Ten year mortality by tumor size

2018.7

6

8

10

12

14

16

18

20

2 1 6 1.54.1

9.5

0

2

4

<1 1‐1.9 2‐2.9 3‐3.9 4‐8.0 >8

2 1.6 1.5

Bilimoria 2007. Annals Surg 207: 375-84

10 Year recurrence rates by tumor size10 Year recurrence rates by tumor size

ates

52,173 patients with papillary thyroid cancer

10

15

20

25

4.6 7.18.6

11.6

17.2

24.8p<0.001 for each pair‐wise comparison

ve r

ecu

rren

ce r

a

Bilimoria 2007 Ann Surg 246: 375

0

5

<1 cm 1‐1.9 cm 2‐2.9 cm 3‐3.9 cm 4‐8 cm >8 cm

Cu

mu

lati

9

Initial TreatmentInitial TreatmentInitial Treatmentand

Long-Term Management

Initial Treatmentand

Long-Term Managementgg

es

50

N T4 RAI

Recurrence Rates as a Function of Treatment

Recurrence Rates as a Function of Treatment

cen

t R

ecu

rren

ce 40

30

20

10

No T4 or RAI

T4 alone

p<0.5

p<0.001

Years After Initial Therapy

Per

c 10

050 10 15 20 25 30 35 40

T4 + RAI

Mazzaferri 1994 Am J Medicine

10

Levels of TSH SuppressionLevels of TSH Suppression

Disease Status

TSH(mU/L)

Duration of Therapy StrengthofStatus (mU/L) of

evidence

Persistent Disease

<0.1 Indefinitely in absence of contraindications

B

NED; High risk tumor

0.1-0.5 10 years then low risk range

C

NED; Low risk tumor

0.3-2.0 Indefinite in absence of recurrence

B

Derived from: Cooper et al. 2009 Thyroid 12: 1-48

Role of Thyroglobulin in Diagnostic F/U

Role of Thyroglobulin in Diagnostic F/U

• Important modality to monitor patients for residual or recurrent diseasefor residual or recurrent disease

• In absence of antibody interference, Tg has high sensitivity and specificity to detect thyroid cancer

Highest sensitivity is following thyroid• Highest sensitivity is following thyroid hormone withdrawal or stimulation using rhTSH

Cooper, D. S., et. al. 2009 Thyroid 19(12) 1-48.

11

Diagnostic value of standard testingDiagnostic value of standard testing

Pacini 2003. JCEM 88 (8): 3668-3673.

Criteria for absence of persistent tumorCriteria for absence of persistent tumor

After total or near-total thyroidectomy and remnant ablation (RAI), disease-free status comprises ALL of

1.No clinical evidence of tumor.

2.No imaging evidence of tumor.

the following:

3.Undetectable serum Tg levels during TSH suppression and stimulation in the absence of interfering antibodies.

Cooper, et al 2009 Thyroid 12: 1-48

12

Contemporary Surgical Contemporary Surgical Management of Differentiated Management of Differentiated

Thyroid CancerThyroid Cancer

Contemporary Surgical Contemporary Surgical Management of Differentiated Management of Differentiated

Thyroid CancerThyroid Cancer

Matthew Old, MD, F.A.C.S.Assistant Professor

Department of Otolaryngology-Head & Neck Surgery

Thyroid CancerThyroid CancerThyroid CancerThyroid Cancer

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital

and Richard J. Solove Research Institute

OutlineOutlineOutlineOutlinePreoperative Assessment

Risk Stratification

Goals

Surgical management

Neck Dissection

Complications and Minimizing Risks

Cases

13

Preoperative AssessmentPreoperative Assessment

Preoperative AssessmentPreoperative Assessment

- Risk stratification

- Preoperative counseling/informed consent based on risk stratification

- Known or suspected cancer: Ultrasound contralateral lobe, central and lateral

k- necks

- FNA suspicious nodes

- Routine use of MRI, CT, PET not needed

Cooper, et al 2009 Thyroid 19: 1167-1214.

14

Risk StratificationRisk Stratification

Risk StratificationRisk StratificationGoal: place patient in a low or high risk

category based on preoperative assessment

Example: Follicular or Hurthle cell neoplasm ~20% risk

High Risk Features

>4 cm>4 cm

Atypical features or suspicious on FNA

Family history

Radiation exposure


15

Surgical GoalsSurgical Goals

Goals Thyroid Cancer SurgeryGoals Thyroid Cancer Surgery

Curative vs Palliative

Remove primary tumory

Remove disease extending outside primary

Remove all nodes involved

Staging

Facilitate postoperative RAI

Permit adequate surveillance (WBS + Tg)

Minimize disease recurrence and mets


16

Extent of SurgeryExtent of SurgeryExtent of Surgery (lobectomy versus

total)

Extent of Surgery (lobectomy versus

total)

Extent of SurgeryExtent of SurgeryThyroid lobectomy – initial approach

- Low risk undiagnosed tumors- Low risk undiagnosed tumors

- DTC <1 cm without contralateral nodules or nodes on US and no high risk factors or features

- 1-2 cm DTC: 24% chance recurrence, 49% increased mortality with lobectomy aloney y

-Individuals >45 - total thyroidectomy for tumors <1cm


17

Extent of SurgeryExtent of SurgeryTotal thyroidectomy

- High risk stratification with unknown or

equivocal FNA

- Improved survival with increased extent of surgery

- All patients with >1cm thyroid cancer with no contraindication to surgery


Neck Dissection(central +/- lateral)Neck Dissection

(central +/- lateral)

18

Neck dissectionNeck dissection

+/-

Adopted from Gray’s Anatomy, Wikipedia Commons

LateralCentral

19

Post-ND AnatomyPost-ND Anatomy

Neck dissectionNeck dissection- General teaching: PTC lymph node metastases in low-

risk patients not clinically significant

- 2 SEER studies recently demonstrated:

1) lymph node metastases, age >45 years, distant mets, larger tumors predicted poor outcome

2) lymph node mets independent for decreased survival only in follicular cancer and PTC in pts over age 45age 45.

- Regional recurrence higher with nodal mets and ECS

Podnos et al 2005 Am Surg 71: 731-734Cooper, et al 2009 Thyroid 19: 1167-1214.Zaydfudium et al 2008 133: 1070-1077

20

Neck dissectionNeck dissection- Risks and benefits should be weighed with surgical

expertise

- Level I and VII (below manubrium) may be involved

- En-bloc, functional neck dissections favored over isolated

lymphadenectomy (“cherry-picking”) with some data to

suggest improved mortality and reduced recurrence

- Most common site of recurrence is in cervical

lymph nodes, which comprise the majority of

all recurrences


Neck dissectionNeck dissection- Central neck dissection (VI) and lateral neck for

clinically involved nodes during total y gthyroidectomy: Rating B

- Consider prophylatic central neck dissection with clinically uninvolved central nodes: Rating C

- Total thyroidectomy without prophylatic central y y p p yneck dissection for T1 or T2, node-negative PTCs, and most follicular cancers: Rating C


21

Minimizing Risks + Maximizing OutcomeMinimizing Risks +

Maximizing Outcome- Preoperative counseling and assessment critical

Hypoparathyroidism bilateral central neck- Hypoparathyroidism – bilateral central neck

dissections

- Debate: preoperative and post-operative vocal

fold assessment

- Discussion of recurrent laryngeal nerve injuryy g j y

and sacrifice – higher incidence with thyroid

cancers

- Chyle leaks, hematomas

- Accessory (CNXI) paresis

ParapreservationParapreservation

22

Post-nerve Dissection Anatomy

Post-nerve Dissection Anatomy

Level IV; Thoracic duct

Level IV; Thoracic duct

23

Case1 –Low risk Case1 –Low risk

35 year old female

2 cm left nodule2 cm left nodule

No family history or risks

FNA – indeterminant

No vocal fold dysfunction

+/ D h i+/- Dysphagia

US – no lateral or central

adenopathy

Case 1 Case 1 Left thyroid lobectomy – frozen: follicular neoplasm

Nerve stuck to backsideNerve stuck to backside

of gland but dissected free

Patient did well without sequelae

Path: 2 cm angioinvasive

unencapsulated follicular thyroid carcinoma

Patient underwent completion thyroidectomy and is without evidence of disease

24

Case 2 Case 2

60 year old male with hoarseness

Right neck and thyroid mass (5 cm)

Right vocal fold paralysis

No family history or risk factors

CT scan performed

Case 2 Case 2

FNA – papillary thyroid carcinoma

25

Case 2 Case 2

Bilateral central and lateral disease; confirmed by US

Case 2 Case 2 Total thyroidectomy, bilateral central

d l t l k di tiand lateral neck dissections, sacrifice of right RLN and right IJ

Path: 5 cm PTC, capsular/perineural/lymphovasculacapsular/perineural/lymphovascular/ deep neck muscular invasion; 15/79 nodes positive with ECS

26

Case 2 Case 2 Required vocal fold medialization

recovered near-normal voice

Post-operative RAI

No evidence of disease to date

Baseline functional status – voice, swallowing and function

new perspectives in thyroid cancer - osu center for ... - thyroid cancer final - 2.pdf · new...

Documents